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Abstract
ARC (Apoptosis Repressor with Caspase recruitment domain) inhibits both death receptor- and
mitochondrial/ER-mediated pathways of apoptosis. While expressed mainly in terminally
differentiated cells, ARC is markedly upregulated in a variety of human cancers, where its
potential contributions have not yet been defined. In this study, we provide evidence of multiple
critical pathophysiological functions for ARC in breast carcinogenesis. In the polyoma middle T-
antigen (PyMT) transgenic mouse model of breast cancer, where endogenous ARC is strongly
upregulated, deletion of the ARC-encoding gene nol3 decreased primary tumor burden without
affecting tumor onset or multiplicity. More notably, ARC deficiency also limited tumor cell
invasion and the number of circulating cancer cells, markedly reducing the number of lung
metastases. Conversely, ectopic overexpression of ARC in a PyMT-derived metastatic breast
cancer cell line increased invasion in vitro and lung metastasis in vivo. We confirmed these results
in a humanized orthotopic model based on MDA-MB-231-derived LM2 metastatic breast cancer
cells, in which RNAi-mediated knockdown of ARC levels was demonstrated to reduce tumor
volume, local invasion, and lung metastases. Lastly, we found that endogenous levels of ARC
conferred chemoresistance in primary tumors as well as invading cell populations. Our results
establish that ARC promotes breast carcinogenesis by driving primary tumor growth, invasion and
metastasis as well as by promoting chemoresistance in invasive cells.
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Introduction
Breast cancer is the second most common cause of cancer deaths in women with mortality
attributable to the metastatic spread to vital organs such as lung, liver, and bone (1).
Furthermore, the resistance of invasive cells to cancer therapies is a major barrier to patient
survival (2). Therefore, an improved understanding of the endogenous factors that mediate
tumorigenesis, invasion, metastasis, and treatment resistance is essential for improving
outcome. Both promotion of cellular proliferation and suppression of apoptosis are critical
for carcinogenesis (3), and proteins that control these processes are often dysregulated (4).
Defects in apoptosis have been implicated in multiple aspects of carcinogenesis including
the survival of transformed cells, resistance to hypoxia, metastasis, and resistance to various
therapeutic agents (3–6).
ARC (Apoptosis Repressor with Caspase Recruitment Domain) is an endogenous inhibitor
of apoptosis (7, 8) that has the unusual property of antagonizing both the extrinsic (death
receptor) and intrinsic (mitochondrial/ER) pathways (9). We and others have delineated
molecular mechanisms that mediate these actions including direct interactions of ARC with
(a) Fas, FADD, and procaspase-8, which interfere with DISC assembly (9); (b) Bax, that
suppress Bax conformational activation and mitochondrial translocation (9, 10); and (c) p53
that inhibit p53 transcriptional function and nuclear localization (11).
Under normal conditions, ARC is abundant primarily in terminally differentiated cells such
as cardiac and skeletal myocytes and neurons (7, 8). ARC expression is strongly
upregulated, however, in a wide variety of cancer cell lines (12–16). Moreover, we and
others have noted that ARC levels are markedly increased in primary human epithelial
cancers including breast, colon, cervical, and ovarian compared with the corresponding
normal tissues (12, 13), as well as in acute myelogenous leukemia (AML) (17). Increases in
ARC protein levels in some cancers, including breast, are mediated by Ras signaling through
both transcriptional activation of nol3, the locus encoding ARC, and stabilization of the
ARC protein (18). Microarray analyses indicate that ARC expression is a predictor of
invasion and metastasis in humans (19, 20), and high ARC levels prognosticate decreased
survivorship in glioblastoma multiforme (16) and AML (17). Moreover, manipulation of
ARC levels in cancer cell lines has been shown to regulate their sensitivities to various
chemotherapies (12, 16, 18, 21, 22).
Although the induction of ARC in human cancers is well established, the functional
relevance of this protein to the pathogenesis of any cancer is not known. In this study, we
employed a combination of genetically-manipulated mice and xenograft studies to delineate
the role of ARC in the pathogenesis of breast cancer from tumor onset through metastasis.
The data demonstrate that ARC is a previously unrecognized regulator of multiple aspects of
breast carcinogenesis and modulates the sensitivities of both primary tumors and the
invading cell population to chemotherapy.
Materials and Methods
Plasmids, viruses, cells
Retrovirus encoding ARC-HA (9) was generated using pBabe-Neo (Addgene) in 293T
Phoenix amphotropic packaging cells (ATCC) (23). pLKO.1-puro, containing shRNA
sequences targeted to human ARC (3’UTR: TRCN0000118447 (shRNA 47) or coding
region: TRCN0000118448 (shRNA 48)) or a control shRNA (Sigma), was used to generate
lentivirus in HEK293T cells (23, 24). LM2 (subline 4175) (25) cells (provided by Drs. S.
Tavazoie and J. Massagué) and Met-1 cells (26) (provided by Dr. Jeffrey Pollard) were
stably transduced with virus using Polybrene 8μg/mL (Sigma), and pools of cells studied.
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Cells derived from the provided starting isolates were passaged for no more than 2–3
months. The Met-1 cells were authenticated by Dr. Pollard in the past year by demonstrating
continued expression of PyMT and the absence of rejection when transplanted into FVB
mice. The LM2 cells have been characterized extensively by Dr. Massague (25).
Generation of PyMT; nol3−/− mice
We generated mice with generalized deletion both alleles of nol3 (encompassing the entire
open reading frame of ARC) and backcrossed them onto a C57Bl/6 background as described
(27). The absence of ARC protein in hearts of nol3−/− mice is shown in Supplementary Fig.
S1. These mice were backcrossed 6 times onto an FVB background and then crossed with
FVB mice hemizygous for an MMTV-PyMT transgene (28). As shown in Fig. 1, PyMT;
nol3−/−mammary tumors lack ARC protein, while PyMT; nol3+/+ tumors express it
abundantly.
Tissue/protein isolation and western blotting
Cells and tissues were lysed using RIPA buffer with protease inhibitors. Mammary epithelial
organoids were isolated as described (18). SDS-PAGE was performed with 20–40μg of
protein under reducing conditions and transferred to nitrocellulose membranes (9).
Immunoblotting was performed with rabbit polyclonal antisera against ARC (Cayman,
1:2000) and a mouse monoclonal antibody against β-actin (Sigma, 1:10,000), and analyzed
with a Li-Cor Odyssey system.
Immunohistochemistry and histological analyses
Tissues were fixed in 10% neutral buffered formalin and immunohistochemistry performed
as described (18) using the ARC antisera (Cayman, 1:500) or a mouse monoclonal antibody
against Ki67 (Novocastra,1:200), and counterstained with hematoxylin. TUNEL was
performed using ApopTag®Plus In Situ Apoptosis Detection Kit (Chemicon). Lung
metastases were analyzed using 6 sections spaced at 300 μM from a whole embedded lung
and stained with hematoxylin & eosin (PyMT mice and Met-1 tail vein injections) or
vimentin (Novocastra 1:500) (LM2 xenograft model). Images of stained slides were
obtained with a Nikon Eclipse TE2000-S microscope and Spot R/T CCD camera.
Invasion and blood burden assays
In vitro invasion assay was performed as described with BD BioCoat Matrigel Invasion
Chambers (BD 354480) using 2.5 × 104 Met-1 cells and 10% FBS as chemoattractant over a
22 hour incubation. In vivo invasion assay was performed as described (29) with EGF (25
nM) used as chemoattractant. Cells were collected for 4 h, stained with DAPI, and counted
(29). Blood burden was assessed as described (30) and tumor cell colonies from blood were
grown in 20% FBS/DMEM media and counted 7 days after plating.
Met-1 tail vein injections and LM2 xenograft model
Experimental metastasis was assessed by injecting 0.5×106 mouse Met-1 cells suspended in
300μl of sterile PBS in the tail vein of 8 week old female FVB mice, and lung metastases
analyzed 14 d later as described above. Mammary xenografts were produced by injecting
human LM2 cells stably expressing luciferase (1 × 106 cells in 100μl of sterile PBS
containing 20% rat tail collagen (BD)) into the lower right mammary gland of 6 w old
female SCID mice (National Cancer Institute). Tumor volume was determined by caliper
measurements (0.5 × length × width2) or bioluminescence imaging. Spontaneous lung
metastases were scored 8 w post-injection as above.
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In vivo bioluminescence imagining and analysis
Mice with xenografts were injected with D-luciferin potassium salt (150 mg/kg ip, Caliper
Life Sciences) for tumor detection or VivoGlo Caspase-3/7 Substrate (z-DEVD-
Aminoluciferin sodium salt, 50 mg/kg ip, Promega,) for apoptosis detection. Anesthetized
mice were imaged 12–15 minutes after injection using the Xenogen IVISR 200 series
system with Living Image software (Caliper Life Sciences) for acquisition and analysis.
Bioluminescence intensity plots are quantified as photon flux (p/sec/cm2/sr) for the region of
interest (ROI) as selected by the auto ROI tool.
Chemosensitivity assays
LM2 cells were plated at a density of 700 cells/mm2 and treated with indicated doses of
doxorubicin (Sigma) for 24 h. Cell death was quantified with calcein AM/ethidium bromide
(Sigma) and counterstaining with Hoechst 33342 (10 μg/ml, Invitrogen) as described (31).
SCID mice bearing LM2 mammary xenografts were injected with doxorubicin 5mg/kg when
tumors reached a volume of ~100 cm3 (calipers), and apoptosis analyzed 72 hours post-
injection by bioluminescence as above. The chemosensitivity of the invading cell
population, captured from PyMT mice using the in vivo invasion assay above, was
determined as described (32). Cells were cultured overnight, and sensitivities to 3 h
treatments with doxorubicin (5 μM) or tamoxifen (5 μM, Sigma) assessed using FACS
analysis of Annexin V/7-AAD stained cells (Guava Technologies). Cells positive for
Annexin V or double positive for Annexin V and 7-AAD were considered dead.
Statistical analyses
Data are expressed as mean ± SEM. Differences were determined using Student’s unpaired
two-tailed t test (2 groups) or ANOVA with Bonferroni post-test (≥ 3 groups) using Prism 5
(GraphPad Software). P < 0.05 was considered significant.
Results
ARC expression is induced in mammary tumors of PyMT mice
We have previously demonstrated that ARC is abundant in primary human breast cancers,
but absent or expressed at very low levels in normal breast tissue (12). Our initial approach
to assessing the functional importance of ARC in breast carcinogenesis was to employ mice
hemizygous for a polyoma middle T-antigen (PyMT) transgene expressed in the mammary
epithelium under the control of mouse mammary tumor virus (MMTV) long terminal
repeats (hereafter referred to as PyMT mice) (28). The PyMT model is highly penetrant and
replicates critical aspects of the human disease including progression from primary tumors
to metastases (33). The rationale for selecting an aggressive model was to provide an
especially challenging target for subsequent rescue experiments. To determine if this is a
suitable model in which to study the effects of ARC on mammary carcinogenesis, we first
assessed whether ARC expression is induced in PyMT mice. Transgenic expression of
PyMT markedly increased the abundance of ARC protein in mammary tumors of various
stages, including adenomas/mammary intraepithelial neoplasia (MIN) and invasive
carcinoma, compared with non-transgenic mice (Fig. 1A, top row). ARC expression was
evident in each tumor of each PyMT mouse, although intensity of immunostaining varied
mildly among tumors. The specificity of the antisera is indicated by the absence of ARC
immunostaining in PyMT mice in which both nol3 alleles were deleted (Fig. 1A, bottom
row). Similar results were evident by Western blotting (Fig. 1B). Interestingly, ARC
expression persisted in metastases dissected from lung tissue (Fig. 1C). These data
demonstrate that ARC expression is induced in early tumors to metastases of PyMT mice,
suggesting that ARC may be involved in multiple stages of mammary carcinogenesis.
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Endogenous ARC promotes tumor burden, but does not affect tumor onset or multiplicity
To assess the role of ARC in mammary carcinogenesis, we employed mice with generalized
deletion of both nol3 alleles. In the absence of a PyMT transgene, nol3 null mice
demonstrated no baseline abnormalities and, specifically, exhibited no mammary pathology
(not shown). When hemizygous for an MMTV-PyMT transgene, nol3 null mice were born
in Mendelian proportions and without detectable abnormalities. Mammary tumors first
became palpable in both PyMT; nol3+/+ and PyMT; nol3−/− mice at 7 w of age (P NS), and
by 10 w of age, 100% of mice of each genotype exhibit at least one tumor (Fig. 2A). Thus,
the presence of ARC does not influence tumor onset. Similarly, tumor multiplicity was not
affected by ARC (Fig. 2B). In contrast, tumor burden, the wet weight of all excised tumors,
differed markedly between PyMT; nol3+/+ and PyMT; nol3−/− mice. While differences were
not yet evident at 12 w, deletion of nol3 reduced tumor burden 34% (9.41 ± 0.78 g in PyMT;
nol3+/+ mice versus 6.19 ± 0.48 g in PyMT; nol3−/− mice; P < 0.0001) at 14 w when tumor
size is at the maximum acceptable limit (Fig. 2C). Thus, endogenous levels of ARC promote
increases in tumor burden, which likely reflect increases in individual tumor mass because
tumor multiplicity is unchanged.
Endogenous ARC promotes tumorigenesis through increased proliferation rather than
decreased apoptosis
To determine the mechanisms by which ARC increases tumor burden in PyMT mice, we
analyzed mammary tumors for apoptosis and proliferation at 14 w of age. The difference in
the number of TUNEL-positive tumor cells per field between PyMT; nol3+/+ and PyMT;
nol3−/− mice was not statistically significant despite studying 8–10 mice of each genotype
(15.4 ± 1.3 cells per field in PyMT; nol3+/+ versus 17.2 ± 1.3 in PyMT; nol3−/−; P NS) (Fig.
2D). While this is surprising in light of the established role of ARC as an apoptosis inhibitor,
it indicates that differences in apoptosis rates do not account for effects on tumor burden. In
contrast, cellular proliferation, as measured by Ki67 staining, was 44% lower in PyMT;
nol3−/−, as compared with PyMT; nol3+/+, mice(356.9 ± 20.8 in PyMT; nol3+/+ miceversus
201.2 ± 20.0 in PyMT; nol3−/− mice; P < 0.0001) (Fig. 2E). These data indicate that
endogenous levels of ARC promote proliferation of mammary cancer cells in vivo, thereby
contributing to increased tumor burden.
Endogenous ARC promotes invasion and metastasis
The high frequency with which primary mammary tumors metastasize in the PyMT model
allowed us to evaluate the effect of ARC on invasion and metastasis. We first determined
whether ARC influences local invasion in vivo by assessing the abilities of tumor cells to
gain access into needles containing Matrigel that had been permeated with EGF as a
chemoattractant. The needles were inserted directly into the primary mammary tumors.
Needles in tumors of PyMT; nol3−/− mice captured 44% less cells than those in tumors of
PyMT; nol3+/+ mice (716.0 ± 69.3 cells per needle in PyMT; nol3+/+ mice versus 399.0 ±
57.7 in PyMT; nol3−/− mice; P < 0.05) (Fig. 3A). These data indicate that ARC promotes
local invasion in vivo, a key step in metastatic progression.
Following invasion, tumor cells may gain access to blood or lymph by intravasating into
blood vessels or lymphatics, a prelude to distant metastasis. The concentration of tumor cells
in blood or lymph reflects rates of intravasation minus extravasation. Accordingly, we next
assessed the concentration of tumor cells circulating in the blood or blood burden. The blood
burden of PyMT; nol3−/− mice was 40% lower than that of PyMT; nol3+/+ mice (927.3 ±
105.5 colonies per ml blood in PyMT; nol3+/+ mice versus 560.3 ± 118.6 in PyMT; nol3−/−
mice; P < 0.05) (Fig. 3B). Differences in plating efficiencies were excluded using primary
tumor cells from the two genotypes (not shown).
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To assess the effect of ARC on the onset and number of lung metastases, we analyzed
hematoxylin & eosin-stained sections. Metastases were not detectable in either genotype at
10 w of age. At 12 w, 6/14 PyMT; nol3+/+ mice and 5/11 PyMT; nol3−/− mice contained at
least one lung metastasis (P NS), indicating similar times of initiation of metastasis in both
genotypes. At 14 w, 100% of the mice in both groups exhibited at least one detectable lung
metastasis. Importantly, however, the number of lung metastases was 44% lower in PyMT;
nol3−/−, as compared with PyMT; nol3+/+, mice (12.0 ± 1.6 in PyMT; nol3+/+ versus 7.0 ±
1.7 in PyMT; nol3−/−mice; P < 0.05) (Fig. 3C, left graph). Even following normalization to
tumor burden, the number of metastases remains significantly reduced in the mice with nol3
deletion (P < 0.01) (Fig. 3C, right graph). These data indicate that endogenous levels of
ARC facilitate lung metastasis.
Converse effects from ARC overexpression
The above experiments assessed effects of ARC absence. Conversely, we wished to evaluate
the effect of ARC overexpression. Met-1 cells are a metastatic mouse mammary tumor cell
line derived from PyMT mice (26). Despite our demonstration of ARC expression in lung
metastases from PyMT mammary tumors in vivo (Fig. 1C), the Met-1 line does not contain
endogenous ARC, making them suitable for gain of function studies. Accordingly, we
generated Met-1 cells with stable with overexpression of ARC (Fig. 3D). In light of our
results showing a significant effect of ARC deletion on invasion in vivo, we first tested
ARC-overexpressing Met-1 cells in an in vitro invasion assay. Using a modified Boyden
chamber assay (34) with Matrigel as the barrier, Met-1 cells expressing exogenous ARC
demonstrated 64% more invasion than cells transduced with empty vector (24.7 ± 4.5 cells
per field in vector-transduced cells versus 40.6 ± 5.8 ARC-transduced cells; P < 0.05) (Fig.
3E). Statistically significant differences were not obtained in the absence of Matrigel
indicating that the observed effects likely reflect invasion rather than motility (not shown).
To assess whether ARC overexpression facilitates lung metastasis, we employed tail vein
injection assays, which bypass the local invasion and intravasation steps required for
spontaneous metastasis in the PyMT model. When injected into the tail vein of syngeneic
wild type FVB female mice, Met-1 cells overexpressing ARC resulted in 1.7-fold more lung
metastases than did the vector control group (53.8 ± 9.1 in mice injected with vector control-
transfected cells versus 92.1 ± 9.6 in mice receiving in ARC-overexpressing cells; P < 0.01)
(Fig. 3F). Thus, ARC overexpression in Met-1 cells promotes post-intravasation metastatic
efficiency.
Endogenous ARC promotes tumorigenesis, invasion, and metastasis in a humanized
model of breast cancer
To test our findings in a humanized breast cancer model, we employed human LM2 cells, a
subset of MDA-MB-231 cells that have a tropism to metastasize to lung (25). Our approach
was to knock down ARC in these cells, xenograft them into the mammary glands of SCID
mice, and assess tumorigenesis, invasion, and metastasis. In contrast to the generalized
knockout of nol3 studied earlier, this model also allows us to assess whether the various
phenotypes result from deficiency of ARC specifically in breast cancer cells.
ARC levels were reduced using lentiviral transduction of different shRNAs (Fig. 4A). ARC
shRNA 48, which results in 72% knockdown in ARC levels (Fig. 4A), reduces xenograft
tumor volume most markedly (Fig. 4B). At 9 w post-transplantation, volume of tumors
derived from ARC shRNA 48-expresssing cells is decreased 42% compared with those
expressing control shRNA (2475 ± 217 mm3 with control shRNA versus 1428 ± 142 mm3
with ARC shRNA 48; P < 0.0001). ARC shRNA 47, which decreases ARC levels less
dramatically (57%) (Fig. 4A), results in an intermediate decrease in tumor volume, although
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statistical significance was not achieved (Fig. 4B). We wished to detect ARC-dependent
changes in tumor volume at even earlier time points when caliper measurements are not
feasible. As the LM2 cells have been engineered to express luciferase, we detected ARC-
dependent differences in tumor volume using bioluminescence. Compared with transplanted
cells expressing control shRNA, those expressing ARC shRNA 48 exhibit markedly smaller
tumors at 3 w post-transplantation (9.86 × 109 ± 1.01 × 109 p/s/r/cm2/sr (photon flux) with
control shRNA versus 3.46 × 109 ± 3.05 × 108 with ARC shRNA 48; P < 0.001), a finding
that is suggested even at 2 w, although statistical significance is not yet present at this time
point (Fig. 4C).
We next assessed local invasion from LM2 tumors using the in vivo invasion assay. ARC
knockdown resulted in 64% less invading cells (407.3 ± 18.1 cells/needle with control
shRNA versus 148.2 ± 10.4 with ARC shRNA 48; P < 0.0001) (Fig. 4D). Mice were also
monitored for spontaneous lung metastases as assessed by immunostaining with an antibody
specific for human vimentin. At 8 w post-transplantation, the number of lung metastases was
62% less in mice receiving LM2 cells with ARC knockdown (419.7 ± 100.1 metastases per
section with control shRNA versus 157.8 ± 63.6 with ARC shRNA 48; P < 0.05) (Fig. 4E).
Thus, as in PyMT mice (Figs. 2C, 3A, 3C), these data show that endogenous levels of ARC
promote increased tumor volume, local invasion, and metastasis in a humanized model of
breast cancer. Moreover, cell autonomous mechanisms are sufficient to account for this
effect.
Endogenous ARC confers chemoresistance to tumors and invading cell population
We next determined whether ARC affects the susceptibility of primary mammary tumors
and the invading cell population to chemotherapy. Cultured LM2 cells with ARC
knockdown were more sensitive to killing by doxorubicin than controls (Fig. 5A). To assess
potential effects of ARC on the susceptibility of primary tumors to chemotherapy in vivo, we
measured the apoptotic response of LM2 tumors to doxorubicin. This was accomplished
with bioluminescence using z-DEVD-aminoluciferin, which requires cleavage by
caspases-3/7 to function as a luciferase substrate. ARC knockdown dramatically potentiated
the apoptotic response of tumors to doxorubicin (Fig. 5B, bars 3 and 4; P < 0.05). Moreover,
while tumors deficient in ARC responded to doxorubicin (Fig. 5B, bars 2 and 4; P < 0.05),
control tumors exhibited no significant changes in apoptosis following treatment (Fig. 5B,
bars 1 and 3; P NS). These data indicate that endogenous levels of ARC confer
chemoresistance to primary tumors.
The ability of primary tumor cells to invade locally is an important factor in the
development of distant metastases, and the invading cell population is known to be more
chemoresistant than primary tumor cells (32). Accordingly, using the PyMT model, we
exploited the in vivo invasion assay to capture locally invading cells, enabling us to assess
the effect of ARC on their resistance to chemotherapy. Deletion of nol3 markedly
augmented killing by doxorubicin (P < 0.05) (Fig. 5C) and tamoxifen (P < 0.001) (Fig. 5D).
We conclude that endogenous levels of ARC contribute to chemoresistance of the invading
cell population.
Discussion
These results indicate that ARC, previously recognized as a regulator of cell death solely in
terminally differentiated cells (e.g. cardiac myocytes), promotes multiple aspects of breast
carcinogenesis. This conclusion is supported by experiments in both genetically manipulated
mice and xenografts of human breast cancer cells. Importantly, our studies emphasize
genetic loss of function to provide insight into the importance of endogenous ARC levels.
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Our previous discovery that ARC abundance is markedly increased in human breast cancers
is recapitulated in mammary tumors of MMTV-PyMT transgenic mice (Fig. 1). Based on
prior studies (18), we presume that ARC levels are increased, in part, through upregulation
of Ras signaling by the PyMT transgene (35). The persistence of ARC from primary tumors
through metastases in this model is in accordance with our results demonstrating
involvement of ARC in pathogenesis at multiple stages. In fact, ARC expression is even
higher in the invading cell population than in corresponding primary mammary tumors of
PyMT mice (unpublished data, S. Goswami and J. Condeelis).
Onset and multiplicity of PyMT tumors are unaffected by the loss of ARC suggesting that
ARC is not necessary for tumor initiation. Rather, our data indicate that ARC strongly
influences tumor growth (Fig. 2C). Despite its known function as an apoptosis inhibitor, the
absence of ARC does not significantly increase apoptosis in this system (Fig. 2D). Although
the explanation for this is not clear, we hypothesize the presence of redundant cell death
inhibitors. Surprisingly, the absence of ARC reduces cellular proliferation (Fig. 2E). This
proliferation function of ARC has not been previously described, although we have recently
observed that ARC knockdown/knockout also impairs the proliferation of benign MCF-10A
breast epithelial cells (unpublished data, C. Medina-Ramirez and R. Kitsis) and hypoxic
pulmonary arterial smooth muscle cells in vivo (27). The mechanism of ARC-induced
cellular proliferation is not known. While the ability of ARC to inactivate p53 may be
involved (11), this explanation is less likely in PyMT tumors in which activated Akt (35)
would be predicted to have already decreased p53 levels through MDM2-mediated
degradation (36).
ARC does not influence the kinetics with which lung metastases develop in the PyMT
model. Rather, the number of lung metastases in PyMT mice lacking ARC is markedly
reduced suggesting decreases in the efficiency of this process. The mechanisms by which
ARC affects invasion and metastasis appear complex. Absence of ARC reduces local
invasion, blood burden (reflecting the balance between intravasation and extravasation), and
metastasis by similar amounts (40–44%) (Fig. 3A, B, C), implying that the most proximal
event, invasion, may play the rate-limiting role. Of note, significant effects of ARC on
invasion were observed in all systems studied (PyMT (Fig. 3A), met-1 (Fig. 3E), and LM2
(Fig. 4D)). While the mechanisms by which ARC facilitates invasion are unclear, emerging
evidence suggests that other cell death regulators (e.g., procaspase-8, IAPs, Bcl-2) may
promote invasion by effects independent of their apoptosis functions (37–41). Procaspase-8,
in particular, promotes migration and metastasis through interactions with a focal adhesion
kinase (FAK) complex (40, 41). Since ARC and procaspase-8 interact (8, 9) we tested the
possibility that the effects of ARC on invasion involve procaspase-8, but found no evidence
in support of this model (K. Bacos and D. Stupack, not shown). In addition to the effects of
ARC on invasion, administration of cancer cells by tail vein to bypass invasion and
intravasation steps still demonstrates that ARC increases the efficiency of lung metastasis
(Fig. 3F). A large proportion of injected cells are known to die rapidly in the circulation and/
or the lung parenchyma (42). This lack of persistence limits the ability of these cells to form
macrometastases. Accordingly, it is likely that ARC confers a post-intravasation survival
advantage that increases the efficiency lung metastasis. These data suggest that ARC
regulates invasion and metastasis at multiple steps.
The effects of ARC on tumor growth, invasion and metastasis observed in the PyMT model
were reproduced using LM2 xenografts (Fig. 4). The significance of this is two-fold. First,
these experiments translate our findings in mouse cells to a humanized model of breast
cancer. Second, these data indicate that ARC exerts cell autonomous effects in mammary
carcinogenesis, a conclusion that could not be drawn from PyMT mice that lack ARC in
non-tumor, as well as, tumor cells.
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We have shown that ARC confers resistance to killing by doxorubicin using human Hs578T
(12) and LM2 (Fig. 5A) cells. The LM2 xenografts provide a useful preclinical model to test
the contributions of ARC to chemoresistance in vivo. Endogenous levels of ARC by
themselves are sufficient to render cells of the primary tumor resistant to doxorubicin-
induced death (Fig. 5B). In this situation, the anti-apoptosis function of ARC is clearly
involved. The increased chemoresistance of the invading cell population (32) poses an
particularly challenging barrier to effective treatment. Our experiments, in which cells
captured in the process of invading are tested for their sensitivities to doxorubicin and
tamoxifen, demonstrate that ARC is a critical factor in the chemoresistance of this
population (Fig 5C, D).
In conclusion, ARC promotes multiple aspects of breast carcinogenesis including
tumorigenesis, invasion, metastasis, and chemoresistance. Given these multiple roles, ARC
may provide a particularly potent target for future therapies directed against breast cancer.
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Figure 1.
ARC protein expression in PyMT tumors. (A) Immunohistochemical staining for ARC
(brown) with hematoxylin counterstain (nuclei, blue) in 8–14 w old virgin female FVB mice
of the indicated genotypes. (B) Western blot analysis of ARC in epithelium isolated from
WT mammary glands and from PyMT mammary carcinomas (5 different mice). (C)
Western blot analysis of ARC in paired mammary tumor and dissected macroscopic lung
metastasis from the same mice.
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Figure 2.
Absence of ARC reduces mammary tumor burden in PyMT mice by reducing cellular
proliferation. (A) Tumor onset. (B) Tumor multiplicity. (For (A) and (B), n = 17 nol3+/+ and
31 nol3−/− mice). (C) Tumor burden. (12 w: n= 28 nol3+/+ and 25 nol3−/− mice; 14 w: n =
22 nol3+/+ and 26 nol3−/− mice). (D) TUNEL. (E) Ki67 staining. (For (D) and (E), n = 10
nol3+/+ and 8 nol3−/−14 w old mice, with ≥ 10 fields (200X) scored per mouse). P values:
****< 0.0001.
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Figure 3.
ARC promotes invasion and metastasis in PyMT model. (A) In vivo invasion assay (see text)
in PyMT mice (n = 3 nol3+/+ and 3 nol3−/− mice with 6 separate needles per mouse). (B)
Blood burden assay in PyMT mice (n = 13 nol3+/+ and 10 nol3−/− mice). (A) and (B)
performed on 12–14 w old mice matched for similar tumor sizes. (C) Left graph: Number of
observable lung metastases in 14 w old PyMT mice (n = 22 nol3+/+ and 26 nol3−/− mice).
Analysis includes all mice regardless of tumor burden. Right graph: Number of observable
lung metastases in mice with similar tumor burdens (nol3+/+ 7.8 ± 0.3 g (n = 8) and nol3−/−
8.1 ± 0.2 g (n = 12); P NS). All mice with tumor burdens in the mid-range (7.0–9.0 g, see
Fig. 2C) were analyzed. (D) Western blot for ARC in Met-1 cells stably transduced with
vector or ARC-HA. (E) Met-1 in vitro invasion assay with an 8 μm PET membrane coated
with Matrigel and 10% FBS as chemoattractant. (n = 4 independent experiments in triplicate
with 5 fields (200×) examined per well). (F) Number of lung metastases 14 d following tail
vein injection of Met-1 cells and representative H&E stained section showing metastases
(purple) (n = 22 (vector) and 23 (ARC-HA) mice). P values: * < 0.05, ** < 0.01.
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Figure 4.
ARC promotes tumorigenesis, invasion, and metastasis in mice with human LM2 mammary
xenografts. (A) Western blot for ARC in LM2 cells stably expressing control shRNA or
shRNAs targeted to ARC 3’UTR (shRNA 47) or coding region (shRNA 48). (B) Effect of
ARC knockdown on tumor volume of LM2 xenografts as determined by caliper
measurements (see Methods) (n = 15 (control shRNA), 5 (ARC shRNA 47), and 11 (ARC
shRNA 48) mice). (C) Effect of ARC knockdown on tumor volume of LM2 xenografts at
very early time points as reflected by bioluminescence (n = 7 (control shRNA) and 8 (ARC
shRNA 48) mice). (D) Effect of ARC knockdown on in vivo invasion (see text) from LM2
xenografts (n = 3 (control shRNA) and 6 (ARC shRNA 48) mice). (E) Effect of ARC
knockdown on spontaneous lung metastasis at 8 w from LM2 xenografts (n = 8 (control
shRNA) and 8 (ARC shRNA 48) mice). P values: * < 0.05, *** < 0.001, **** <0.0001.
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Figure 5.
Endogenous ARC levels confer chemoresistance. (A) Effect of ARC knockdown on
sensitivity of cultured LM2 cells to killing by doxorubicin as scored by the number of
ethidium bromide-positive/total cells (Hoechst 33342) (n = 2 independent experiments in
triplicate, > 10 fields (200X) scored per sample) and representative phase contrast
micrograph. (B) Effect of ARC knockdown on apoptosis in LM2 mammary xenografts 72 h
post-treatment with single dose of doxorubicin (5 mg/kg ip) as measured by
bioluminescence using a luciferin substrate that requires prior cleavage by endogenous
caspases-3/7. (n = 8 mice in each group). (C) and (D) Sensitivity of captured invading cells
from PyMT; nol3+/+ and PyMT; nol3−/− mice to killing by doxorubicin (5 μM) (C) or
tamoxifen (5 μM) (D) as assessed by FACS analysis of Annexin V/7-AAD stained cells. (n
= 3–4 mice per group). P values: * < 0.05, ** < 0.01, *** < 0.001.
Medina-Ramirez et al. Page 16
Cancer Res. Author manuscript; available in PMC 2012 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
